Spinraza FDA Approval History
FDA Approved: Yes (First approved December 23, 2016)
Brand name: Spinraza
Generic name: nusinersen
Dosage form: Injection
Treatment for: Spinal Muscular Atrophy
Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Development Timeline for Spinraza
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.